Answer
Breastfeeding should be discontinued during treatment with belumosudil mesilate (Rezurock) and for at least one week after the last dose because of potential serious adverse reactions in the breastfed child.
Sources for this answer
- REZUROCK 200 mg film-coated tablets.SANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked